Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Predicting extended hospital stay after deep brain stimulation surgery in Parkinson's patients.

Young NA, Brown MP, Peng J, Kline D, Reider C, Deogaonkar M.

J Clin Neurosci. 2019 Nov;69:241-244. doi: 10.1016/j.jocn.2019.07.042. Epub 2019 Aug 17.

PMID:
31431404
2.

Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.

Mencel J, Gargett T, Karanth N, Pokorny A, Brown MP, Charakidis M.

Asia Pac J Clin Oncol. 2019 Dec;15(6):383-386. doi: 10.1111/ajco.13233. Epub 2019 Aug 1.

PMID:
31373116
3.

Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy.

Burdett N, Hsu K, Xiong L, Tapia-Rico G, Beckmann K, Karapetis C, Brown MP.

Asia Pac J Clin Oncol. 2019 Jun 19. doi: 10.1111/ajco.13177. [Epub ahead of print]

PMID:
31215775
4.

Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma.

Brown MP, Ebert LM, Gargett T.

Clin Transl Immunology. 2019 May 20;8(5):e1050. doi: 10.1002/cti2.1050. eCollection 2019. Review.

5.

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.

Gargett T, Truong N, Ebert LM, Yu W, Brown MP.

Cytotherapy. 2019 Jun;21(6):593-602. doi: 10.1016/j.jcyt.2019.03.003. Epub 2019 Apr 8.

PMID:
30975603
6.

Serum Levels of Prealbumin and Albumin for Preoperative Risk Stratification.

Loftus TJ, Brown MP, Slish JH, Rosenthal MD.

Nutr Clin Pract. 2019 Jun;34(3):340-348. doi: 10.1002/ncp.10271. Epub 2019 Mar 25. Review.

PMID:
30908744
7.

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.

Perrin SL, Samuel MS, Koszyca B, Brown MP, Ebert LM, Oksdath M, Gomez GA.

Biochem Soc Trans. 2019 Apr 30;47(2):625-638. doi: 10.1042/BST20180444. Epub 2019 Mar 22. Review.

PMID:
30902924
8.

Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells.

Zhang P, Raju J, Ullah MA, Au R, Varelias A, Gartlan KH, Olver SD, Samson LD, Sturgeon E, Zomerdijk N, Avery J, Gargett T, Brown MP, Coin LJ, Ganesamoorthy D, Hutchins C, Pratt GR, Kennedy GA, Morton AJ, Curley CI, Hill GR, Tey SK.

Clin Cancer Res. 2019 Mar 15;25(6):1749-1755. doi: 10.1158/1078-0432.CCR-18-3069. Epub 2019 Feb 14.

PMID:
30765390
9.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
10.

APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo.

Staudacher AH, Li Y, Liapis V, Hou JJC, Chin D, Dolezal O, Adams TE, van Berkel PH, Brown MP.

Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.

PMID:
30413648
11.

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.

Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A, Ruszkiewicz A, Atmosukarto IIC, Altin J, Parish CR, Brown MP.

Cancer Immunol Immunother. 2018 Sep;67(9):1461-1472. doi: 10.1007/s00262-018-2207-z. Epub 2018 Jul 16.

PMID:
30014244
12.

Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay.

Reid P, Wilson P, Li Y, Marcu LG, Staudacher AH, Brown MP, Bezak E.

Sci Rep. 2018 May 17;8(1):7744. doi: 10.1038/s41598-018-26134-9.

13.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.

Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

PMID:
29602646
14.

Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.

Ebert LM, Yu W, Gargett T, Brown MP.

Biochem Soc Trans. 2018 Apr 17;46(2):391-401. doi: 10.1042/BST20170178. Epub 2018 Mar 14. Review.

PMID:
29540509
15.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M.

Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13.

16.

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Staudacher AH, Brown MP.

Br J Cancer. 2017 Dec 5;117(12):1736-1742. doi: 10.1038/bjc.2017.367. Epub 2017 Oct 24. Review.

17.

In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status.

Reid P, Wilson P, Li Y, Marcu LG, Staudacher AH, Brown MP, Bezak E.

PLoS One. 2017 Oct 13;12(10):e0186186. doi: 10.1371/journal.pone.0186186. eCollection 2017.

18.

Varicose and cheerio collaborate with pebble to mediate semaphorin-1a reverse signaling in Drosophila.

Jeong S, Yang DS, Hong YG, Mitchell SP, Brown MP, Kolodkin AL.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8254-E8263. doi: 10.1073/pnas.1713010114. Epub 2017 Sep 11.

19.

Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer.

Takhar H, Singhal N, Mislang A, Kumar R, Kim L, Selva-Nayagam S, Pittman K, Karapetis C, Borg M, Olver IN, Brown MP.

Asia Pac J Clin Oncol. 2018 Feb;14(1):91-100. doi: 10.1111/ajco.12749. Epub 2017 Aug 25.

PMID:
28840978
20.

A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.

Tadesse S, Zhu G, Mekonnen LB, Lenjisa JL, Yu M, Brown MP, Wang S.

Future Med Chem. 2017 Sep;9(13):1495-1506. doi: 10.4155/fmc-2017-0076. Epub 2017 Aug 10.

PMID:
28795589
21.

The laminar organization of the Drosophila ellipsoid body is semaphorin-dependent and prevents the formation of ectopic synaptic connections.

Xie X, Tabuchi M, Brown MP, Mitchell SP, Wu MN, Kolodkin AL.

Elife. 2017 Jun 20;6. pii: e25328. doi: 10.7554/eLife.25328.

22.

An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.

Koci B, Luerman G, Duenbostell A, Kettenhofen R, Bohlen H, Coyle L, Knight B, Ku W, Volberg W, Woska JR Jr, Brown MP.

Toxicol Appl Pharmacol. 2017 Aug 15;329:121-127. doi: 10.1016/j.taap.2017.05.023. Epub 2017 May 22.

PMID:
28546047
23.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
24.

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Tan LY, Martini C, Fridlender ZG, Bonder CS, Brown MP, Ebert LM.

Clin Transl Immunology. 2017 Mar 17;6(3):e134. doi: 10.1038/cti.2017.7. eCollection 2017 Mar. Review.

25.

Letters.

Finlay S, Brown MP, Moats J.

Nursing. 2017 Apr;47(4):8. doi: 10.1097/01.NURSE.0000513614.42938.aa. No abstract available.

PMID:
28328765
26.

Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.

Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W.

J Neuroimmunol. 2017 Apr 15;305:16-18. doi: 10.1016/j.jneuroim.2016.12.016. Epub 2017 Jan 18.

PMID:
28284337
27.

Risk of cumulative toxicity after complete melanoma response with pembrolizumab.

Hsieh AH, Faithfull S, Brown MP.

BMJ Case Rep. 2017 Feb 1;2017. pii: bcr2016218308. doi: 10.1136/bcr-2016-218308.

28.

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong AS.

Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9. No abstract available.

PMID:
28129558
29.

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.

Gargett T, Christo SN, Hercus TR, Abbas N, Singhal N, Lopez AF, Brown MP.

Clin Transl Immunology. 2016 Dec 23;5(12):e119. doi: 10.1038/cti.2016.80. eCollection 2016 Dec.

30.

Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy.

Al Darwish R, Staudacher AH, Li Y, Brown MP, Bezak E.

Med Phys. 2016 Nov;43(11):6145.

PMID:
27806616
31.
32.

Vedolizumab: a novel treatment for ipilimumab-induced colitis.

Hsieh AH, Ferman M, Brown MP, Andrews JM.

BMJ Case Rep. 2016 Aug 18;2016. pii: bcr2016216641. doi: 10.1136/bcr-2016-216641.

33.

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S.

Aust Fam Physician. 2015 Dec;44(12):875-6. No abstract available.

PMID:
27505912
34.

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM.

Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.

35.

MAGNETIC RESONANCE IMAGING SCORING OF AN EXPERIMENTAL MODEL OF POST-TRAUMATIC OSTEOARTHRITIS IN THE EQUINE CARPUS.

Smith AD, Morton AJ, Winter MD, Colahan PT, Ghivizzani S, Brown MP, Hernandez JA, Nickerson DM.

Vet Radiol Ultrasound. 2016 Sep;57(5):502-14. doi: 10.1111/vru.12369. Epub 2016 May 19.

36.

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP.

Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.

37.

The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Brown MP, Bezak E, Allen BJ.

Melanoma Manag. 2015 Nov;2(4):353-366. doi: 10.2217/mmt.15.26. Epub 2015 Nov 24. Review.

38.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

39.

Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer.

Takhar HS, Singhal N, Gowda R, Penniment M, Takhar P, Brown MP.

Anticancer Drugs. 2015 Nov;26(10):1069-77. doi: 10.1097/CAD.0000000000000282.

PMID:
26317683
40.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.

Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.

PMID:
26310975
41.

Multiplexed highly-accurate DNA sequencing of closely-related HIV-1 variants using continuous long reads from single molecule, real-time sequencing.

Dilernia DA, Chien JT, Monaco DC, Brown MP, Ende Z, Deymier MJ, Yue L, Paxinos EE, Allen S, Tirado-Ramos A, Hunter E.

Nucleic Acids Res. 2015 Nov 16;43(20):e129. doi: 10.1093/nar/gkv630. Epub 2015 Jun 22.

42.

Circumferential hoof clamp method of lameness induction in the horse.

Swaab ME, Mendez-Angulo JL, Groschen DM, Ernst NS, Brown MP, Trumble TN.

Vet J. 2015 Jul;205(1):81-6. doi: 10.1016/j.tvjl.2015.03.026. Epub 2015 Mar 25.

PMID:
26045357
43.

Autoradiography imaging in targeted alpha therapy with Timepix detector.

A L Darwish R, Staudacher AH, Bezak E, Brown MP.

Comput Math Methods Med. 2015;2015:612580. doi: 10.1155/2015/612580. Epub 2015 Jan 22.

44.

Scrutinizing calcium flux oscillations in T lymphocytes to deduce the strength of stimulus.

Christo SN, Diener KR, Nordon RE, Brown MP, Griesser HJ, Vasilev K, Christo FC, Hayball JD.

Sci Rep. 2015 Jan 14;5:7760. doi: 10.1038/srep07760.

45.
46.
47.

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.

J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061.

PMID:
25415284
48.

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.

Gargett T, Brown MP.

Front Pharmacol. 2014 Oct 28;5:235. doi: 10.3389/fphar.2014.00235. eCollection 2014. Review.

49.

Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia.

Roder DM, Fong KM, Brown MP, Zalcberg J, Wainwright CE.

Eur J Cancer Care (Engl). 2014 Nov;23(6):721-7. doi: 10.1111/ecc.12242. Epub 2014 Sep 22.

PMID:
25244252
50.

Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.

Staudacher AH, Bezak E, Borysenko A, Brown MP.

Nucl Med Commun. 2014 Dec;35(12):1284-90. doi: 10.1097/MNM.0000000000000199.

PMID:
25192189

Supplemental Content

Loading ...
Support Center